Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Transformative Period Led by Acquisition of TeraImmune

Company to Prioritize Development of New TI-168 Treg Asset for Hemophilia A

Read more at globenewswire.com